Literature DB >> 16977474

Bone mineral density in children with chronic renal failure.

Simon Waller1, Deborah Ridout, Lesley Rees.   

Abstract

Bone mineral density (BMD) is important in children and adolescents because of its relationship to long-term skeletal health, and because, in adults with chronic renal failure (CRF), a relationship between low BMD and vascular calcification has been suggested. To investigate the relationship between BMD and manipulable factors that might affect it, i.e. plasma calcium, phosphate and parathyroid hormone (PTH), 64 patients with a median glomerular filtration rate (GFR) of 31 (range 7-60) ml min(-1) 1.73 m(-2) and median age of 10.0 (4.1-16.9) years were followed over 1.3 (0.7-1.7) years at an average of 5 (3-14) clinic visits. At one visit, BMD of the lumbar spine was measured by dual energy X-ray absorptiometry. The mean BMD Z-score was normal (=0.0). Overall mean calcium, phosphate and PTH levels were in their respective normal ranges. The majority of the patients (72%) were treated with calcium carbonate, mean dose 65 mg kg(-1) day(-1); prescription was positively related to serum calcium levels and calcium-phosphate product (P=0.012 and P<0.01 respectively). Almost all patients (98%) were treated with alfacalcidol, mean dose 12 ng kg(-1) day(-1); prescription was not related to investigated factors. Patients grew well; there was no change in height standard deviation score (DeltaHtSDS=0.0). Normal BMD Z-score for age and sex can be achieved in children with CRF managed with the aim of maintaining normal PTH levels by dietary phosphate restriction, calcium-based phosphate binders and small doses of alfacalcidol. Further investigation of the underlying bone by the use of biopsy and histomorphometry is required to determine actual bone health.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16977474     DOI: 10.1007/s00467-006-0292-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  46 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Bone mineral content, corrected for height or bone area, measured by DXA is not reduced in children with chronic renal disease or in hypoparathyroidism.

Authors:  S Faisal Ahmed; Shiuli Russell; Rajeeb Rashid; T James Beattie; Anna V Murphy; Ian J Ramage; Heather Maxwell
Journal:  Pediatr Nephrol       Date:  2005-07-27       Impact factor: 3.714

3.  Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis.

Authors:  A Gerakis; D Hadjidakis; E Kokkinakis; T Apostolou; S Raptis; A Billis
Journal:  J Nephrol       Date:  2000 Nov-Dec       Impact factor: 3.902

4.  Bone density measurements in pediatric patients with renal osteodystrophy.

Authors:  Eleonora M Lima; William G Goodman; Beatriz D Kuizon; Barbara Gales; Aletha Emerick; Jonathan Goldin; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2003-04-24       Impact factor: 3.714

5.  Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism.

Authors:  Esra Baskin; Seza Ozen; Musturay Karçaaltincaba; Nesrin Besbas; Umit Saatci; Ali Düzova; Pinar Isik Agras; Mithat Haliloglu; Aysin Bakkaloglu
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis.

Authors:  J M Saland; M L Goode; D L Haas; T A Romano; M G Seikaly
Journal:  Am J Transplant       Date:  2001-09       Impact factor: 8.086

7.  Weight-/height-related bone mineral density is not reduced after renal transplantation.

Authors:  G Klaus; C Paschen; C Wüster; G T Kovacs; J Barden; O Mehls; K Schärer
Journal:  Pediatr Nephrol       Date:  1998-06       Impact factor: 3.714

8.  Mineralized bone loss at different sites in dialysis patients: implications for prevention.

Authors:  H C Schober; Z H Han; A J Foldes; M S Shih; D S Rao; R Balena; A M Parfitt
Journal:  J Am Soc Nephrol       Date:  1998-07       Impact factor: 10.121

9.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

Authors:  N A Hamdy; J A Kanis; M N Beneton; C B Brown; J R Juttmann; J G Jordans; S Josse; A Meyrier; R L Lins; I T Fairey
Journal:  BMJ       Date:  1995-02-11

10.  A chart to link child centiles of body mass index, weight and height.

Authors:  T J Cole
Journal:  Eur J Clin Nutr       Date:  2002-12       Impact factor: 4.016

View more
  7 in total

1.  Longitudinal assessment of bone quality in pediatric patients with chronic kidney disease in relation to treatment modality.

Authors:  Chrysa Gkogka; Athanasios Christoforidis; Nikoleta Printza; Konstantinos Kollios; Eirini Kazantzidou; Fotios Papachristou
Journal:  J Bone Miner Metab       Date:  2014-05-25       Impact factor: 2.626

Review 2.  Imaging chronic renal disease and renal transplant in children.

Authors:  Jim Carmichael; Marina Easty
Journal:  Pediatr Radiol       Date:  2010-04-30

3.  Volumetric bone mineral density and bone structure in childhood chronic kidney disease.

Authors:  Rachel J Wetzsteon; Heidi J Kalkwarf; Justine Shults; Babette S Zemel; Bethany J Foster; Lindsay Griffin; C Frederic Strife; Debbie L Foerster; Darlene K Jean-Pierre; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

4.  Assessment of dual-energy X-ray absorptiometry measures of bone health in pediatric chronic kidney disease.

Authors:  Lindsay M Griffin; Heidi J Kalkwarf; Babette S Zemel; Justine Shults; Rachel J Wetzsteon; C Frederic Strife; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2012-02-16       Impact factor: 3.714

5.  Skeletal effects and growth in children with chronic kidney disease: a 5-year prospective study.

Authors:  Diana Swolin-Eide; Sverker Hansson; Per Magnusson
Journal:  J Bone Miner Metab       Date:  2012-12-10       Impact factor: 2.626

Review 6.  Nephrolithiasis and Nephrocalcinosis in Childhood-Risk Factor-Related Current and Future Treatment Options.

Authors:  Alexander Weigert; Bernd Hoppe
Journal:  Front Pediatr       Date:  2018-04-12       Impact factor: 3.418

Review 7.  Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?

Authors:  A D Lalayiannis; N J Crabtree; M Fewtrell; L Biassoni; D V Milford; C J Ferro; R Shroff
Journal:  Pediatr Nephrol       Date:  2019-06-25       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.